3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Anus Neoplasms
1
Anal Canal Carcinoma
1
Interventions
pembrolizumab
37
Paclitaxel
18
Cisplatin
18
Carboplatin
14
Nivolumab
13
Hyperthermic Intraperitoneal Chemotherapy
13
Docetaxel
11
Cyclophosphamide
11
Oxaliplatin
9
Irinotecan
9
Fluorouracil
9
atezolizumab
8
Trastuzumab
8
Leucovorin
8
Bevacizumab
8
fludarabine
7
Magnetic Resonance Spectroscopy
7
Specimen Handling
6
Ipilimumab
6
Gemcitabine
6
Mitomycin
5
Cytoreduction Surgical Procedures
5
Capecitabine
5
durvalumab
4
cemiplimab
4
aldesleukin
4
Taxes
4
Psychiatric Rehabilitation
4
Platinum
4
Drug Therapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
rocakinogene sifuplasmid
×
Gynecologic
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled